177 related articles for article (PubMed ID: 30486884)
1. Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results.
Mackiewicz J; Burzykowski T; Iżycki D; Mackiewicz A
J Immunother Cancer; 2018 Nov; 6(1):134. PubMed ID: 30486884
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection.
Mackiewicz A; Mackiewicz J; Wysocki PJ; Wiznerowicz M; Kapcinska M; Laciak M; Rose-John S; Izycki D; Burzykowski T; Karczewska-Dzionk A
Expert Opin Investig Drugs; 2012 Jun; 21(6):773-83. PubMed ID: 22577889
[TBL] [Abstract][Full Text] [Related]
3. Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma.
Mackiewicz J; Karczewska-Dzionk A; Laciak M; Kapcinska M; Wiznerowicz M; Burzykowski T; Zakowska M; Rose-John S; Mackiewicz A
Medicine (Baltimore); 2015 May; 94(21):e853. PubMed ID: 26020391
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
[TBL] [Abstract][Full Text] [Related]
5. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
[TBL] [Abstract][Full Text] [Related]
6. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
7. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
8. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
11. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
[TBL] [Abstract][Full Text] [Related]
12. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.
Sarnaik AA; Yu B; Yu D; Morelli D; Hall M; Bogle D; Yan L; Targan S; Solomon J; Nichol G; Yellin M; Weber JS
Clin Cancer Res; 2011 Feb; 17(4):896-906. PubMed ID: 21106722
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
[TBL] [Abstract][Full Text] [Related]
14. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
15. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
Vreeland TJ; Clifton GT; Hale DF; Chick RC; Hickerson AT; Cindass JL; Adams AM; Bohan PMK; Andtbacka RHI; Berger AC; Jakub JW; Sussman JJ; Terando AM; Wagner T; Peoples GE; Faries MB
Ann Surg Oncol; 2021 Oct; 28(11):6126-6137. PubMed ID: 33641012
[TBL] [Abstract][Full Text] [Related]
16. Clinical prognostic markers in stage IIIC melanoma.
Madu MF; Schopman JHH; Berger DMS; Klop WMC; Jóźwiak K; Wouters MWJM; van der Hage JA; van Akkooi ACJ
J Surg Oncol; 2017 Aug; 116(2):244-251. PubMed ID: 28411392
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
Carson WE; Unger JM; Sosman JA; Flaherty LE; Tuthill RJ; Porter MJ; Thompson JA; Kempf RA; Othus M; Ribas A; Sondak VK
Cancer Immunol Res; 2014 Oct; 2(10):981-7. PubMed ID: 24994597
[TBL] [Abstract][Full Text] [Related]
18. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.
Wallack MK; Sivanandham M; Ditaranto K; Shaw P; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Rosen L; Bartolucci AA
Ann Surg; 1997 Aug; 226(2):198-206. PubMed ID: 9296514
[TBL] [Abstract][Full Text] [Related]
19. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
20. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM; Schneble EJ; Jackson DO; Hale DF; Vreeland TJ; Flores M; Martin J; Herbert GS; Hardin MO; Yu X; Wagner TE; Peoples GE
Cancer Immunol Immunother; 2016 Apr; 65(4):383-92. PubMed ID: 26894495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]